Article
Oncology
Mathew Cowan, Wendy M. Swetzig, Valery Adorno-Cruz, Mario J. Pineda, Nikki L. Neubauer, Emily Berry, John R. Lurain, Shohreh Shahabi, Deanna Taiym, Valerie Nelson, Kaitlyn Lucrezia O'Shea, Masha Kocherginsky, Daniela Matei
Summary: The study evaluated the activity of Tivozanib in patients with recurrent, platinum-resistant ovarian cancer, demonstrating a certain level of efficacy with partial responses in some patients. The drug showed moderate toxicity and no treatment-related deaths, indicating potential for further development.
GYNECOLOGIC ONCOLOGY
(2021)
Review
Oncology
Siyu Li, Tao Wang, Xichang Fei, Mingjun Zhang
Summary: Platinum-resistant ovarian cancer is a deadly cancer with a poor prognosis, and ATR inhibitors have shown promising results in its treatment.
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Platinum-resistant ovarian cancer is associated with poor prognosis and limited treatment options. Combination treatment with immunotherapy, anti-angiogenic therapy, and chemotherapy can significantly extend progression-free survival in these patients.
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Ovarian cancer is a common gynecologic cancer in the US, and platinum-resistant disease has a poor prognosis. This study suggests that treatment with immunotherapy followed by anti-angiogenic therapy and chemotherapy can improve survival in patients with platinum-resistant ovarian cancer. The experience of three patients showed significantly longer progression-free survival compared to previous averages.
Article
Oncology
Michelle McMullen, Ainhoa Madariaga, Stephanie Lheureux
Summary: Platinum drugs are crucial in ovarian cancer treatment, but resistance is a major challenge, with complex mechanisms involving both intracellular and microenvironment factors. Clinical trials are essential for improving outcomes, and future research should focus on understanding the biology of the disease and enhancing quality of life and survival for patients.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Madhavi Manyam, Amanda J. Stephens, Jessica A. Kennard, Jane LeBlanc, Sarfraz Ahmad, James E. Kendrick, Robert W. Holloway
Summary: The study demonstrated promising safety, clinical activities, and immune activation of intraperitoneal Olvi-Vec virotherapy in patients with platinum-resistant or refractory ovarian cancer (PRROC), indicating the need for further clinical investigation.
GYNECOLOGIC ONCOLOGY
(2021)
Review
Oncology
Alice Indini, Olga Nigro, Csongor Gyorgy Lengyel, Michele Ghidini, Angelica Petrillo, Salvatore Lopez, Francesco Raspagliesi, Dario Trapani, Shelize Khakoo, Giorgio Bogani
Summary: Patients with platinum-resistant ovarian cancer have a poor prognosis with limited treatment options. While single-agent immunotherapy has shown disappointing results, combining immunotherapy with target therapies like PARP inhibitors and TKIs appears promising. Ongoing trials are evaluating these combination strategies to assess their impact and cost-effectiveness.
Review
Biochemistry & Molecular Biology
Carolina Maria Sassu, Innocenza Palaia, Serena Maria Boccia, Giuseppe Caruso, Giorgia Perniola, Federica Tomao, Violante Di Donato, Angela Musella, Ludovico Muzii
Summary: Ovarian cancer is the second leading cause of death in women with gynecological cancer, with poor prognosis, especially in platinum-resistant disease. Efforts have been made to define new biomarkers, with circulating biomarkers being detected non-invasively but potentially requiring expensive techniques.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
M. Cummings, C. Freer, N. M. Orsi
Summary: Ovarian cancer often presents at an advanced stage and initial response to platinum-based therapies is positive, but chemoresistance develops leading to poor prognosis. The tumor microenvironment has been found to play a central role in therapy resistance and disease progression, making it an attractive therapeutic target. Focus has been on targeting cancer associated fibroblasts, tumor-associated macrophages, cancer stem cells, and cancer cell metabolic vulnerabilities for new therapies.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Panagiotis A. Konstantinopoulos, Jung-Min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin, Ronnie Shapira-Frommer
Summary: This study aimed to evaluate the efficacy and safety of using prexasertib, a CHK1 inhibitor, in treating high-grade serous ovarian cancer. The results showed that prexasertib demonstrated durable single agent activity to a certain extent and its effects were not influenced by clinical characteristics, BRCA status, or prior therapies, including PARPi. The study also emphasized the need for alternative biomarker approaches to identify responders.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Manman Xu, Xi Huang, Cuimiao Zheng, Junming Long, Qingyuan Dai, Yangyang Chen, Jingyi Lu, Chaoyun Pan, Shuzhong Yao, Jie Li
Summary: This study investigates the role of NHEJ in platinum resistance in ovarian cancer and finds that XRCC4 in the NHEJ pathway specifically contributes to resistance by mitigating DNA damage caused by platinum drugs, providing preclinical evidence for targeting XRCC4 as a new strategy to combat cisplatin resistance in ovarian cancer treatment.
Article
Oncology
Francesca Ricci, Alessandro Corbelli, Roberta Affatato, Rosaria Chila, Michela Chiappa, Laura Brunelli, Robert Fruscio, Roberta Pastorelli, Fabio Fiordaliso, Giovanna Damia
Summary: Our study found that acquisition of DDP resistance is associated with morphological alterations in mitochondria, despite the lack of dysregulation in the studied genes/proteins that could explain the observed differences.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Stephanie Gaillard, Ana Oaknin, Isabelle Ray-Coquard, Ignace Vergote, Giovanni Scambia, Nicoletta Colombo, Cristian Fernandez, Vicente Alfaro, Carmen Kahatt, Antonio Nieto, Ali Zeaiter, Miguel Aracil, Laura Vidal, Beatriz Pardo-Burdalo, Zsuzsanna Papai, Rebecca Kristeleit, David M. O'Malley, Ivor Benjamin, Patricia Pautier, Domenica Lorusso
Summary: The CORAIL trial did not find an improvement in progression-free survival with lurbinectedin compared to standard treatments for platinum-resistant ovarian cancer. However, lurbinectedin showed similar antitumor efficacy and better tolerance compared to current standard of care in this patient population.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Chemistry, Medicinal
Suhas S. Bhosale, Abhisek Mandal, Caixia Hou, J. Robert McCorkle, David Schweer, Kristen S. Hill, Vivekanandan Subramanian, Jill M. Kolesar, Oleg V. Tsodikov, Jurgen Rohr
Summary: A new conjugate called mithplatin, which combines the anticancer drug mithramycin with a reactive Pt(II) bearing moiety, has been developed to combat Pt-resistant ovarian cancers. This conjugate showed higher potency than cisplatin and was effective against both Pt-sensitive and Pt-resistant ovarian cancer cells.
Article
Oncology
Leslie M. Randall, David M. O'Malley, Bradley J. Monk, Robert L. Coleman, Stephanie Gaillard, Sarah Adams, Linda R. Duska, Heather Dalton, Robert W. Holloway, Marilyn Huang, Hye Sook Chon, Noelle G. Cloven, Adam C. Elnaggar, Roisin E. O'Cearbhaill, Steven Waggoner, Aarti Tarkar, Alina Striha, Linda M. Nelsen, Amanda Baines, Vivek Samnotra, Panagiotis A. Konstantinopoulos
Summary: This study aimed to evaluate the efficacy, safety, and HRQoL of the dostarlimab and niraparib treatment regimen in patients with BRCAwt PROC. However, the interim futility analysis showed unsatisfactory ORR, leading to termination of the study. This highlights the need for effective treatment strategies for recurrent BRCAwt PROC patients.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Oncology
Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M. Sholl, Keith M. Kerr, Sacha Gnjatic, Ignacio I. Wistuba, David L. Rimm, Ming Sound Tsao, Fred R. Hirsch
Summary: PD-L1 expression is currently the best predictor of responsiveness to immune-checkpoint inhibitors, despite challenges in clinical use such as variability in different assays and cut-off points, as well as the lack of prospective comparisons with clinical outcomes. Nevertheless, several immunohistochemical assays have been approved for clinical use, with implications for pathology services and potential impacts on clinical outcomes. Comparison of FDA-approved PD-L1 assays, understanding of the varying implications of PD-L1 expression across different tumour types, and exploration of novel approaches to optimize its clinical utility are important topics for further research and practice.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Correction
Cell Biology
Jian Carrot-Zhang, Xiaotong Yao, Siddhartha Devarakonda, Aditya Deshpande, Jeffrey S. Damrauer, Tiago Chedraoui Silva, Christopher K. Wong, Hyo Young Choi, Ina Felau, A. Gordon Robertson, Mauro A. A. Castro, Lisui Bao, Esther Rheinbay, Eric Minwei Liu, Tuan Trieu, David Haan, Christina Yau, Toshinori Hinoue, Yuexin Liu, Ofer Shapira, Kiran Kumar, Karen L. Mungall, Hailei Zhang, Jake June-Koo Lee, Ashton Berger, Galen F. Gao, Binyamin Zhitomirsky, Wen-Wei Liang, Meng Zhou, Sitapriya Moorthi, Alice H. Berger, Eric A. Collisson, Michael C. Zody, Li Ding, Andrew D. Cherniack, Gad Getz, Olivier Elemento, Christopher C. Benz, Josh Stuart, J. C. Zenklusen, Rameen Beroukhim, Jason C. Chang, Joshua D. Campbell, D. Neil Hayes, Lixing Yang, Peter W. Laird, John N. Weinstein, David J. Kwiatkowski, Ming S. Tsao, William D. Travis, Ekta Khurana, Benjamin P. Berman, Katherine A. Hoadley, Nicolas Robine, Matthew Meyerson, Ramaswamy Govindan, Marcin Imielinski
Article
Cell Biology
Jian Carrot-Zhang, Xiaotong Yao, Siddhartha Devarakonda, Aditya Deshpande, Jeffrey S. Damrauer, Tiago Chedraoui Silva, Christopher K. Wong, Hyo Young Choi, Ina Felau, A. Gordon Robertson, Mauro A. A. Castro, Lisui Bao, Esther Rheinbay, Eric Minwei Liu, Tuan Trieu, David Haan, Christina Yau, Toshinori Hinoue, Yuexin Liu, Ofer Shapira, Kiran Kumar, Karen L. Mungall, Hailei Zhang, Jake June-Koo Lee, Ashton Berger, Galen F. Gao, Binyamin Zhitomirsky, Wen-Wei Liang, Meng Zhou, Sitapriya Moorthi, Alice H. Berger, Eric A. Collisson, Michael C. Zody, Li Ding, Andrew D. Cherniack, Gad Getz, Olivier Elemento, Christopher C. Benz, Josh Stuart, J. C. Zenklusen, Rameen Beroukhim, Jason C. Chang, Joshua D. Campbell, D. Neil Hayes, Lixing Yang, Peter W. Laird, John N. Weinstein, David J. Kwiatkowski, Ming S. Tsao, William D. Travis, Ekta Khurana, Benjamin P. Berman, Katherine A. Hoadley, Nicolas Robine, Matthew Meyerson, Ramaswamy Govindan, Marcin Imielinski
Summary: Alterations in the RTK/RAS/RAF pathway are a characteristic feature of lung adenocarcinoma (LUAD). A study using whole-genome sequencing of 85 cases initially identified as RPA(-) revealed that around 33% of cases were actually RPA(+). The remaining cases showed genetic mutations associated with tumor suppressor deletions and genome instability.
Article
Oncology
Joel D. Pearson, Katherine Huang, Marek Pacal, Sean R. McCurdy, Suying Lu, Arthur Aubry, Tao Yu, Kristine M. Wadosky, Letian Zhang, Tao Wang, Alex Gregorieff, Mohammad Ahmad, Helen Dimaras, Ellen Langille, Susan P. C. Cole, Philippe P. Monnier, Benjamin H. Lok, Ming-Sound Tsao, Nagako Akeno, Daniel Schramek, Kathryn A. Wikenheiser-Brokamp, Erik S. Knudsen, Agnieszka K. Witkiewicz, Jeffrey L. Wrana, David W. Goodrich, Rod Bremner
Summary: The study identifies two binary cancer classes based on the activity of YAP, providing insights into the impact of cancer heterogeneity on therapeutic response. YAP silencing is intrinsic to the cell of origin and may be acquired with lineage switching and drug resistance.
Meeting Abstract
Oncology
Sofia Genta, Ming Sound Tsao, Ben X. Wang, Aaron Richard Hansen, Trevor John Pugh, Mathieu Lupien, Bryan Coburn, Javier Diaz-Mejia, Marcus O. Butler, Philippe L. Bedard, Albiruni Ryan Abdul Razak, Sevan Hakgor, Vanessa Speers, Heidi Wagner, Laura Tamblyn, Troy Ketela, Dax Torti, Nikolina Radulovich, Lillian L. Siu, Anna Spreafico
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Editorial Material
Oncology
Ming-Sound Tsao, Andrew G. Nicholson, Joseph J. Maleszewski, Alexander Marx, William D. Travis
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Ku-Geng Huo, Hirotsugu Notsuda, Zhenhao Fang, Ningdi Feng Liu, Teklab Gebregiworgis, Quan Li, Nhu-An Pham, Ming Li, Ni Liu, Frances A. Shepherd, Christopher B. Marshall, Mitsuhiko Ikura, Nadeem Moghal, Ming-Sound Tsao
Summary: This study found that clinically approved EGFR TKIs can be used to treat patients with non-small cell lung cancer harboring the BRAF(G469V) mutation. Through experiments with a xenograft model and a cell line, it was confirmed that BRAF G469v is the oncogenic driver in this mutation. Structural modeling and experiments further demonstrated that BRAF(G469V) is a direct target of EGFR TKIs.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Dalam Ly, Quan Li, Roya Navab, Cedric Zeltz, Linan Fang, Michael Cabanero, Chang-Qi Zhu, Ming-Sound Tsao, Li Zhang
Summary: Understanding how the immune system regulates the tumor microenvironment is crucial for the development of effective cancer treatments. This study reveals the adverse prognostic role of LAIR2 expression in regulatory T cells and identifies it as a potential target for future immunotherapies.
Article
Biochemistry & Molecular Biology
Cedric Zeltz, Maryam Khalil, Roya Navab, Ming-Sound Tsao
Summary: Collagen type XI restrains collagen remodeling and cell migration mediated by cancer-associated fibroblasts (CAF), thereby limiting the invasion of lung cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Joshua C. Rosen, Adrian Sacher, Ming-Sound Tsao
Summary: KRAS(G12C) inhibitors have shown promising results in clinical trials with overall response rates ranging between 32% and 46%, and have been granted FDA approvals as second-line or later monotherapies. However, rapid tumor resistance complicates their use as a monotherapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein, Laura Ranich, Adam C. Smith, Cuihong Wei, Carol Cheung, Frances A. Shepherd, Geoffrey Liu, Penelope Bradbury, Prodipto Pal, Joerg Schwock, Adrian G. Sacher, Jennifer H. Law, Tracy L. Stockley, Natasha B. Leighl
Summary: In NSCLC patients, reflex testing using NGS panels can identify actionable genetic variants in the majority of cases with minimal increase in testing cost. Implementation of NGS panels is essential for the treatment of NSCLC patients as treatment paradigms continue to evolve.
Meeting Abstract
Medicine, Research & Experimental
Ellen Yang, Najd Alshamlan, Jessica Weiss, Michael Cabanero, Ming Tsao
LABORATORY INVESTIGATION
(2022)
Meeting Abstract
Oncology
Sally C. M. Lau, Shirin Soleimani, Jinfeng Zou, Justin Burgener, Shelley Kuang, Stephanie W. Y. Wong, Malcolm Ryan, Ben X. Wang, Stephanie Pedersen, Devalben Patel, Penelope A. Bradbury, Geoffrey Liu, Natasha Leighl, Ming S. Tsao, Pamela S. Ohashi, Scott V. Bratman, Trevor Pugh, Frances A. Shepherd, Adrian G. Sacher
Article
Oncology
D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao
Summary: TRK inhibitors larotrectinib and entrectinib have been recently approved in Canada for treating solid tumors with NTRK gene fusions. These gene fusions are found at low frequency in most tumor types, and at higher frequency in rare tumors. The inhibitors have shown impressive efficacy and tolerability in clinical trials. Canada has developed a consensus on testing and treatment for NTRK gene fusions.
Meeting Abstract
Oncology
A. C. L. Lam, R. Aggarwal, J. Huang, K. Hueniken, M. Tsao, F. Shepherd, W. Xu, J. Kavanagh, G. Liu
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)